1-3 of 3
Carissa Laudati
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preliminary safety and efficacy of boven (Zanubrutinib, Obinutuzumab, and Venetoclax) as frontline therapy for older patients with Mantle Cell Lymphoma

Free
Anita Kumar, Jacob Soumerai, Reem Karmali, Jeremy Abramson, Jeffrey Barnes, Bernadette Beatty, Jason Brecher, Philip Caron, Kenneth Carson, Maria Chabowska, Madelyn Coogan, Jayne Coyle, Kevin David, Meemanage De Zoysa, Ahmet Dogan, Zachary Epstein-Peterson, Paola Ghione, Cameron Gordan, Leo Gordon, Julie Haydu, Ephraim Hochberg, Patrick Connor Johnson, Ashlee Joseph, Akshata Kakolu, Alyssa Labarre, Carissa Laudati, Jennifer Lue, Shuo Ma, Rosalba Martignetti, Colette Owens, Olivia Maas, Joanna Mi, Rachel Nazzaro, James O'Grady, Jessica Pendleton, Gilles Salles, Venkatraman Seshan, Natalie Slupe, Pallawi Torka, Andrew Zelenetz
Journal: Blood
Blood (2025) 146 (Supplement 1): 888.
https://doi.org/10.1182/blood-2025-888
Published: 2025
Journal Articles

Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)

Free
Lindsey Roeker, Anthony R. Mato, Andrew D. Zelenetz, Jae H. Park, Mark Blaine Geyer, Andriy Derkach, David Nemirovsky, Prioty Islam, Lorenzo Falchi, Maria Lia Palomba, Anita Kumar, Gilles Salles, Jennifer Kimberly Lue, Aaron D. Goldberg, Deborah M. Stephens, Victoria Duffy, Gail Panton, Dianna Tyznar, Colleen Dorsey, Dhara Soni, Claire Hutzler, Lauren Nogan, Alexandra Allen, Tenzin Nyima, Thu Quynh Nguyen, Monica Shah, Tamotha R Cook, Jennifer Abillar-Wright, Jamila Brutus, Carissa Laudati, Bejal Kikani, Catherine C Coombs, Michael R. Silvestrone, Christopher E. Jensen, Bita Fakhri, Meghan C. Thompson
Journal: Blood
Blood (2024) 144 (Supplement 1): 1010.
https://doi.org/10.1182/blood-2024-203807
Published: 2024
Journal Articles

A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach

Free
Lindsey E. Roeker, Lori A. Leslie, Jake D. Soumerai, Victoria Falco, Gail Panton, Andrew D. Zelenetz, Lorenzo Falchi, Jae H Park, Camila Pena-Velasquez, Sonia Lebowitz, Kristen Battiato, Carissa Laudati, Meghan C. Thompson, David J. Straus, Yehudit Fox, Elizabeth McCarthy, Sabrina Kdiry, Rosalba Martignetti, Hari P. Miskin, Peter Sportelli, Anthony R. Mato
Journal: Blood
Blood (2021) 138 (Supplement 1): 395.
https://doi.org/10.1182/blood-2021-146999
Published: 2021